Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trialGary Middleton, John P. Neoptolemos, Paul Silcocks et al.|The Lancet Oncology|2014Cited by 374
Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 TrialWilliam Greenhalf, Markus W. Büchler, Eithne Costello et al.|JNCI Journal of the National Cancer Institute|2013Cited by 333
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trialGary Middleton, John P. Neoptolemos, Daniel H. Palmer et al.|The Lancet Oncology|2017Cited by 73
S100A8 and S100A9 proteins form part of a paracrine feedback loop between pancreatic cancer cells and monocytesTaoufik Nedjadi, Eithne Costello|BMC Cancer|2018Cited by 57
Identification of Cystic Lesions by Secondary Screening of Familial Pancreatic Cancer (FPC) Kindreds Is Not Associated with the Stratified Risk of CancerAndrea Sheel, Sara Harrison, Ioannis Sarantitis et al.|The American Journal of Gastroenterology|2018Cited by 33